Ophirex Advances Varespladib for Snakebite Treatment Under FDA Animal Rule Pathway
核心洞察
Ophirex (搜索) has secured FDA agreement to develop varespladib for snakebite treatment under the Animal Rule pathway, which permits human approval using animal efficacy data and human safety data.
The oral snakebite treatment has received FDA MUMS designation for dogs and multiple human designations including Orphan Drug, Rare Pediatric Disease, and Fast Track status.
Two completed Phase 2 studies showed mixed results, with the primary endpoint not met in BRAVO but signals of benefit observed in patients treated within five hours of bite.
Ophirex (搜索), Inc. announced significant regulatory progress for varespladib, positioning the oral snakebite treatment as a potential first-of-its-kind rescue therapy that could be administered immediately following venomous snakebites. The FDA has agreed that varespladib development is appropriate under the Animal Rule pathway, which allows drug approval using human safety data combined with efficacy data from well-controlled animal studies.
FDA Animal Rule Pathway Approval
The Animal Rule represents a critical regulatory pathway for addressing emergency medical needs where traditional human efficacy trials may be impractical or unethical. Since 2002, more than 15 drugs have received approval through this mechanism, particularly for treatments addressing critical unmet medical needs in emergency care settings.
"Oral varespladib is a potentially groundbreaking innovation in the treatment of snakebite envenomation (搜索) because it is designed to be used at the time of bite, allowing treatment to be initiated in minutes instead of hours," said Jeremy Gowler, CEO of Ophirex (搜索).
Animal studies of varespladib in envenoming models that mimic human conditions are currently underway. These studies will determine the fully effective dose for snakebite treatment and provide evidence of the breadth of therapeutic benefit across different snake species.
Clinical Development Results
Two Phase 2 studies of varespladib in snakebite envenomation (搜索)—BRAVO and BRAVIO—have been completed in emergency department patients who had already initiated standard-of-care treatment, including antivenom. While the primary endpoint in the BRAVO study was not met, the trial revealed signals consistent with therapeutic benefit in the pre-specified subgroup of patients who received study drug within the first five hours after the bite.
Results from the BRAVIO trial and experimental mouse studies testing varespladib against the most important venomous snakes in the United States are expected to be published in the coming months.
Mechanism of Action and Regulatory Status
Varespladib functions as a small-molecule inhibitor of snake venom secretory phospholipase A2 (搜索) (sPLA2 (搜索)), a class of toxins present in the venom of more than 95% of venomous snake species. The drug rapidly inhibits sPLA2 activity and mitigates downstream toxic effects associated with envenomation.
The treatment has received multiple FDA designations recognizing its potential to address significant unmet medical needs: Orphan Drug, Rare Pediatric Disease, and Fast Track designations for human use. Additionally, varespladib has received MUMS (Minor Use in a Major Species) designation from the FDA Center for Veterinary Medicine for treating snakebite in dogs when antivenom is not immediately available.
Global Health Impact
The development addresses a substantial global health crisis, with approximately 4-5 million venomous snakebites occurring annually worldwide, resulting in approximately 125,000 deaths and 400,000 permanent disabilities. Critically, 75% of snakebite deaths occur prior to hospital arrival, highlighting the urgent need for immediate treatment options.
Strategic Developments
To support expansion into animal health markets, Ophirex (搜索) has appointed Aaron Schacht to its Board of Directors. Schacht brings extensive experience in animal health research and development, regulatory affairs, and business development, including his current role as CEO and Board Director of BiomEdit (搜索) and previous leadership positions at Elanco and Eli Lilly.
The company is developing varespladib with support from the Defense Health Agency's Small Business Innovation Research program and the Operational Medical Systems team under the Broad-Spectrum Snakebite Antidote program. This initiative aims to provide an FDA-approved solution that is shelf-stable, lightweight, cost-effective, easy to use in austere environments, and effective against multiple snake species while reducing the logistical burdens associated with current antivenom treatments.
"An oral treatment for snakebite has the potential to positively impact the 4-5 million people who experience venomous snakebite each year," Gowler stated. "We are committed to being a catalyst for change in how snakebite envenomation (搜索) is treated in the U.S. and around the world."